TransCode Therapeutics, Inc. (RNAZ)

NASDAQ: RNAZ · Real-Time Price · USD

0.4000

+0.0860 (27.39%)

At close: Apr 24, 2025, 4:00 PM

0.4002

+0.0002 (0.05%)

Pre-market: Apr 25, 2025, 6:02 AM EDT

TransCode Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2018 - 2019
Selling, General & Admin	5.95	7.15	8.4	3.4	0.44	Upgrade
Research & Development	9.71	12.26	10.23	2.75	0.28	Upgrade
Operating Expenses	15.66	19.42	18.63	6.15	0.73	Upgrade
Operating Income	-15.66	-19.42	-18.63	-6.15	-0.73	Upgrade
Interest Expense	-0.03	-0.06	-0.03	-0.1	-0.39	Upgrade
Interest & Investment Income	0	0.01	0.02	0	0	Upgrade
Currency Exchange Gain (Loss)	-0.06	-	-	-	-	Upgrade
Other Non Operating Income (Expenses)	-1.01	0.92	1.08	-0.59	-1.22	Upgrade
EBT Excluding Unusual Items	-16.76	-18.55	-17.56	-6.84	-2.34	Upgrade
Gain (Loss) on Sale of Assets	0	-	-	-0	-	Upgrade
Pretax Income	-16.75	-18.55	-17.56	-6.84	-2.34	Upgrade
Net Income	-16.75	-18.55	-17.56	-6.84	-2.34	Upgrade
Net Income to Common	-16.75	-18.55	-17.56	-6.84	-2.34	Upgrade
Shares Outstanding (Basic)	0	-	-	-	-	Upgrade
Shares Outstanding (Diluted)	0	-	-	-	-	Upgrade
EPS (Basic)	-47.05	-	-	-	-	Upgrade
EPS (Diluted)	-47.05	-	-	-	-	Upgrade
Free Cash Flow	-13.36	-18.11	-15.86	-5.52	-0.49	Upgrade
Free Cash Flow Per Share	-37.51	-	-	-	-	Upgrade
EBITDA	-15.57	-19.3	-18.54	-6.11	-	Upgrade
D&A For EBITDA	0.09	0.12	0.1	0.04	-	Upgrade
EBIT	-15.66	-19.42	-18.63	-6.15	-0.73	Upgrade

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q